GR-MD-02 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Sep 1, 2015 → Sep 27, 2016
NCT ID
NCT02421094About GR-MD-02 + Placebo
GR-MD-02 + Placebo is a phase 2 stage product being developed by Galectin Therapeutics for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02421094. Target conditions include Nonalcoholic Steatohepatitis.
What happened to similar drugs?
0 of 6 similar drugs in Nonalcoholic Steatohepatitis were approved
Approved (0) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02421094 | Phase 2 | Completed |
| NCT02462967 | Phase 2 | Completed |
| NCT01899859 | Phase 1 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis